An Australian biotechnology company announced plans to develop a diagnostic kit for prostate cancer that would do away with invasive testing. Proteome Systems Ltd had signed a deal with US cancer diagnostic firm Egenix Inc to develop a test to identify the presence in semen of the human carcinoma antigen (HCA), an indicator of cancer.
